CARI Guidelines: Australian and New Zealand living guideline for chronic kidney disease

Published by David Tunnicliffe on Jun 28, 2024

View

Disclaimer

Sponsors

Contact

Abstract

Language

en-au

PICOS

PICO 10.1

Population
Autosomal dominant polycystic kidney disease Autosomal dominant polycystic kidney ,
Intervention
Metformin Autosomal dominant polycystic kidney ,
Comparator
Placebo Autosomal dominant polycystic kidney ,
Outcomes
Autosomal dominant polycystic kidney ,

PICO 10.1

Population
Autosomal dominant polycystic kidney disease Autosomal dominant polycystic kidney ,
Intervention
Tolvaptan Autosomal dominant polycystic kidney ,
Comparator
Placebo Autosomal dominant polycystic kidney ,
Outcomes
Autosomal dominant polycystic kidney ,

PICO 10.1

Population
People with chronic kidney disease (eGFR ≥15 mL/min/1.73m^2)
Intervention
Statin therapy
Comparator
Placebo or standard of care
Outcomes

PICO 10.1

Population
Kidney transplantation
Intervention
Balanced Electrolyte Solutions
Comparator
Normal Saline for Kidney Transplantation
Outcomes

PICO 10.2

Population
People with chronic kidney disease (eGFR 15 - 90 mL/min/1.73m^2)
Intervention
Statin therapy plus ezetimibe
Comparator
Statin therapy
Outcomes

PICO 10.2

Population
Deceased kidney transplantation
Intervention
Balance electolyte solution
Comparator
Normal saline
Outcomes

PICO 10.3

Population
Living kidney transplantation
Intervention
Balance electolyte solution
Comparator
Normal saline
Outcomes

PICO 20.1

Population
Autosomal dominant polycystic kidney disease
Intervention
Prescribed water intake
Comparator
Ad libitum water intake
Outcomes

PICO 20.1

Population
People with chronic kidney disease (not requiring dialysis) (SMART-C)
Intervention
SGLT2 inhibitors
Comparator
Placebo
Outcomes

PICO 20.2

Population
Chronic kidney disease (not requiring dialysis)
Intervention
SGLT2 inhibitors
Comparator
Placebo
Outcomes

PICO 20.3

Population
Very high risk chronic kidney disease (not requiring dialysis)
Intervention
SGLT2 inhibitors
Comparator
Placebo
Outcomes

PICO 20.4

Population
High risk chronic kidney disease (not requiring dialysis)
Intervention
SGLT2 inhibitors
Comparator
Placebo
Outcomes

PICO 20.5

Population
Moderate risk chronic kidney disease (not requiring dialysis)
Intervention
SGLT2 inhibitors
Comparator
Placebo
Outcomes

PICO 20.6

Population
Low risk chronic kidney disease with diabetes (not requiring dialysis)
Intervention
SGLT2 inhibitors
Comparator
Placebo
Outcomes

PICO 30.1

Population
People with CKD and hyperuricemia (not receiving dialysis)
Intervention
Urate-lowering therapy
Comparator
Placebo / Standard of care / no treatment
Outcomes

PICO 30.2

Population
People with CKD and hyperuricemia (not receiving dialysis)
Intervention
Urate-lowering therapy
Comparator
Placebo / Standard of care / no treatment
Outcomes